Sonic Hedgehog Pathway Modulation in Medulloblastoma: Focus on Vismodegib (GDC-0449)

Medulloblastoma (MB) is the most common malignant brain tumor in children, classified into four molecular subgroups: WNT, sonic hedgehog (SHH), Group 3, and Group 4. The SHH pathway is crucial in the pathogenesis of SHH-subgroup MB (SHH-MB), influenced by mutations in patched homolog 1 (PTCH1), smoothened (SMO), and suppressor-of-fused (SUFU). Targeting this route has shown potential, with vismodegib, an SMO inhibitor, demonstrating effectiveness in both preclinical and clinical investigations. Notwithstanding its therapeutic promise, vismodegib's systemic toxicity, especially bone abnormalities in pediatric patients, constrains its application. Novel techniques, such as nanoparticle formulations and intraventricular administration, have optimized medication distribution, diminished toxicity, and augmented effectiveness. Research indicates vismodegib's efficacy in enhancing progression-free survival (PFS) and addressing tumor-specific genetic abnormalities. Nonetheless, obstacles, such as resistance stemming from SMO mutations and developmental toxicity, remain. Prospects encompass the enhancement of drug delivery methods, the integration of SHH inhibitors with alternative therapeutics, and the advancement of next-generation inhibitors to surmount resistance. Hence, these developments offer potential for improving outcomes in SHH-MB while reducing side effects, especially in pediatric populations.